Targeting CD47-SIRPα not only disrupts the binding of CD47 and SIRPα and potentiates the phagocytosis ability of cancer cells by stimulating macrophage cytokine secretion and thus stimulating the patients’ immune system7,335 but also kills tumor cells through the NK-cell-mediated ADCC effect336 and even directly induces tumor cell apoptosis.337,338 Moreover, targeting CD47 also enables DCs to phagocytize tumor cells, present the tumor antigen to T cells and activates the adaptive immunity. Here, SIRPA is linked to cancer.